Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals to Participate at Upcoming March 2026 Investor Conferences

Key Takeaway: Acadia Pharmaceuticals Inc. has announced its participation in three upcoming investor conferences in March 2026. The events include the TD Cowen's 46th Annual Health Care Conference and The Citizens Life Sciences Conference, where the company will host fireside chats. Live webcasts will be available on their website, showcasing their commitment to investor engagement.
Price reaction · baseline $24.73 (2026-02-23 close) · hit pre-market · 1 other ACAD headline(s) in the window, move may be shared
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Pharmaceuticals is actively engaging with investors.
  • Participation in multiple conferences indicates strong investor interest.
  • The company is committed to innovation in neurological and rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
Pimavanserin
Phase 2 · Agitation and Aggression in Alzheimer's Disease

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:
TD Cowen's 46th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA
The Citizens Life Sciences ConferenceFireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL
Live webcasts will be accessible on the company’s website,acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us atacadia.comand follow us onLinkedInandX.

Frequently Asked Questions

What conferences will Acadia Pharmaceuticals attend?

Acadia Pharmaceuticals will participate in TD Cowen's Health Care Conference and The Citizens Life Sciences Conference.

When is the TD Cowen's conference?

The TD Cowen's 46th Annual Health Care Conference is on March 2, 2026.

Where can I watch the conference webcasts?

Live webcasts will be available on Acadia's website under the investors section.

What is Acadia's focus in their pipeline?

Acadia focuses on neurological and rare diseases, including treatments for Parkinson's disease psychosis.

Last updated: Feb 24, 2026